Our Blog

February 15, 2024
Julian Scoffield Vishal Shankar
Newsletter Corporate CrackdownDepartment of JusticeExecutive BranchHousing
An RDP Love Letter To Picking Fights and Good Punditry
Cracking down on corporate abuses is what government should be for.

February 09, 2024 | The American Prospect
Durbin Must Enforce His SCOTUS Investigation Subpoenas
Uncovering Crow’s and Leo’s full relationships with the Court is precisely the sort of scenario for which Congress has subpoena powers in the first place. As of now, these plutocrats have been able to scoff at the will of elected leaders. Durbin’s actions, or lack thereof, will inform whether history remembers this Congress as stepping up or shrugging off one of the greatest threats to the American legal system in our lifetimes.

February 09, 2024
Celebrating A Year Of All In
Let’s Examine The Tech Dufuses Who’ve Become Twitter’s Economic Pundits As A Result Of Elon’s Algorithm Fixing

February 08, 2024
The Fed's FOIA Office Is Obscuring Its Trading Scandals
In October of 2021, the Federal Reserve was embroiled in scandal. The heads of the Boston and Dallas Feds resigned following personal trading scandals that raised concerns about conflicts of interest and lax ethics guidelines. Further reports of potentially inappropriate trading by Chair Jerome Powell and Vice Chair Clarida rocketed across the business media due to these officials’ immense access to sensitive financial information and influence on monetary policy. Despite their decidedly questionable profiteering off pandemic panic, Powell and Clarida have since had their reputations effectively laundered by the media in a whitewashing effort that has attempted to clear them of all wrongdoing. To make matters worse, the Fed’s FOIA office is doing everything in its power to prevent internal documents relating to the scandals from reaching the light of day.

February 07, 2024
The East Palestine Disaster One Year Later
Biden has yet to visit East Palestine but is expected to do so this month. When he does, he should denounce Norfolk Southern’s avarice from the site of the train wreck.
February 06, 2024
Civil Society Comment on the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
Unfortunately, despite numerous petitions presented over the 40-plus year history of the Bayh-Dole Act, not once has a federal agency exercised its right to march-in and license competition to remedy price gouging (which constitutes a failure of the owner of a subject invention to make that invention available to the public on reasonable terms), or otherwise.

February 05, 2024
Will Jay Powell’s Cheerleaders Ever Admit They Were Wrong?
Soon after Biden renominated Powell, the ostensibly dovish Fed chair embarked on the most intense and sustained series of rate hikes in decades. We were told that this wouldn’t happen!

February 02, 2024
RELEASE: Revolving Door Project Applauds House Dems’ Calls For Biden To Fill Postal Board Vacancies
Letter Co-Signed By 80+ Lawmakers Underscores Louis DeJoy’s Destructive Continued Leadership
February 02, 2024
Conspiracy (Taylor’s Version): On Conservative Crazies, The Media Definition of “Economist,” And Our Humble Little Clown Show
On Conservative Crazies, The Media Definition of “Economist,” And Our Humble Little Clown Show
February 02, 2024
Advocates Thank President Biden and USTR Katherine Tai For Withdrawing Support For Extreme Digital Trade Proposals
RDP joined a coalition of labor unions, nonprofits and activist groups to thank President Biden and United States Trade Representative Katherine Tai for standing firm in support of a worker-centered trade agenda that preserves space for needed public interest policies.

February 02, 2024 | The American Prospect
Biden Should Begin the Tax Wars Now
He needs to highlight his positions against the Republicans’. And not give away too much in interim deals.

January 31, 2024 | Revolving Door Project Newsletter
More Revolvers Join The Fight Against The Regulatory State
The regulatory authority of the executive branch is under attack, and BigLaw firms stacked with revolvers are on the front lines leading the assault. I’ve previously written about former FTC Commissioner Christine Varney challenging the legitimacy of her former employer on behalf of pharma company Illumina. Lawyers at Latham & Watkins, a firm stacked with revolvers from executive branch agencies, are before the Supreme Court challenging the Chevron Doctrine, which defers to executive agencies’ interpretations when legislative statutes are unclear. The Securities and Exchange Commission’s ability to hold administrative proceedings hangs in the balance as we await the Supreme Court’s decision in SEC v. Jarkesy, where the Fifth Circuit’s ruling decimated the agency’s authority. In a new attack, revolvers on the labor/management relations team at Morgan Lewis & Bockius have their sights set on the plutocrats’ latest target: the National Labor Relations Board.

January 29, 2024 | The Sling
To Save the Planet, Biden Should Not Renominate Powell
Inflation is falling, but Jerome Powell has nothing to do with it. Our democracy and climate face mounting instability—and he has everything to do with that.


January 26, 2024
The FTC Ain’t Nothin to Mess With
The FTC has won its lawsuit against Martin Shkreli, the pharmaceutical executive infamous for jacking up the price of the antiparasitic drug Daraprim from $13.50 to $750 overnight in 2015 and later using his ill-gotten fortune to buy an exclusive Wu-Tang Clan album for $2 million. Shkreli is the quintessential corporate ghoul, having already racked up convictions for securities fraud—which resulted in an indefinite ban from the securities industries—and failure to pay $1.26 million in New York state taxes. Now, his price gouging has finally caught up with him, as the FTC successfully argued that he spearheaded an anti-competitive scheme to monopolize the drug. The presiding judge found Shkreli’s conduct to be “egregious, deliberate, repetitive, long-running, and ultimately dangerous,” issuing a $64.6 million fine and imposing a lifetime ban from the pharmaceutical industry.